Wall Street Zen Upgrades SciSparc (NASDAQ:SPRC) to “Hold”

SciSparc (NASDAQ:SPRC) was upgraded by equities researchers at Wall Street Zen to a “hold” rating in a report released on Saturday.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of SciSparc in a research report on Tuesday, May 26th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Sell”.

SciSparc Price Performance

Shares of SciSparc stock opened at $5.00 on Friday. The business has a 50-day simple moving average of $6.51 and a 200 day simple moving average of $6.51. SciSparc has a one year low of $2.98 and a one year high of $80.10.

SciSparc (NASDAQ:SPRC) last announced its quarterly earnings results on Wednesday, April 29th. The company reported ($31.60) earnings per share (EPS) for the quarter. The business had revenue of $0.20 million during the quarter.

SciSparc Company Profile

SciSparc AG is a clinical‐stage medical technology company focused on the development and commercialization of extracorporeal shock wave–based neuromodulation devices. Founded in 2016 and headquartered in Switzerland, the company applies proprietary low‐intensity shock wave technology to noninvasively stimulate neural tissue. SciSparc completed its initial public offering on the NASDAQ in 2021 under the ticker SPRC, securing funding to advance its clinical pipeline.

The company’s lead product, the TR100 system, delivers transcranial shock wave stimulation (tSWS) designed to target areas of the brain associated with motor control and cognitive function.